Lifelong Heterogeneous Contribution of Cardiovascular Risk Factors to Slow and Fast Progression of Arterial Stiffness

Hirofumi Tomiyama1,2, Takumi Imai3, Kazuki Shiina1,2

  • 1Department of Cardiology (H.T., K.S., H.N., T.T., M.F., C.M., T.C.), Tokyo Medical University, Japan.

Insights

Lifelong cardiovascular risk factors (CVRFs) like smoking and hypertension significantly impact arterial stiffness progression. Managing these CVRFs early is crucial for slowing arterial stiffness and maintaining cardiovascular health.

Area of Science:

  • Cardiovascular Health
  • Epidemiology
  • Vascular Biology

Background:

  • Arterial stiffness is linked to cardiovascular risk factors (CVRFs).
  • However, arterial stiffness does not mediate all CVRF-associated cardiovascular risks.
  • The lifelong impact of CVRFs on arterial stiffness progression requires further investigation.

Purpose of the Study:

  • To examine the association between lifelong status of individual CVRFs and the rate of arterial stiffness progression.
  • To provide epidemiological evidence on the heterogeneity of CVRF contributions to arterial stiffness.
  • To inform early intervention strategies for cardiovascular health.

Main Methods:

  • Longitudinal study using repeated measurements over 16 years.
  • Data from annual health checkups including brachial-ankle pulse wave velocity (baPWV).
  • Analysis of a middle-aged Japanese occupational cohort (3763 subjects).

Main Results:

  • 29,090 baPWV measurements were analyzed.
  • Smoking, heavy alcohol intake, hypertension, diabetes, hypertriglyceridemia, and hyperuricemia were linked to fast arterial stiffness progression.
  • Lower levels of blood pressure, HbA1c, triglycerides, and uric acid were associated with slow progression; BMI and LDL-C showed no clear association.

Conclusions:

  • Lifelong CVRF status significantly and heterogeneously influences arterial stiffness progression rates.
  • Findings support the need for early, comprehensive interventions targeting CVRFs from middle age.
  • Controlling CVRFs is vital for both slowing fast arterial stiffness progression and maintaining slow progression.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
20
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
10
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs but also impacts other areas, such as the arms, thereby impairing overall circulation and organ function.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty deposits inside the arterial...
9
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
13
Vascular Resistance01:20

Vascular Resistance

Vascular resistance is a critical concept in understanding blood flow dynamics in the circulatory system. It refers to the resistance that blood encounters as it flows through the blood vessels. This resistance is a key factor in determining blood pressure and cardiac workload.
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
4.3K